Table 1.

The reverse migration of tamoxifen

Treatment settingResults
Tamoxifen vs. DES, 1981 (114)Metastatic diseaseaResponse rate 33% on tamoxifen monotherapy
EBCTCG meta-analysis, 1998 (115)Adjuvant treatment47% decrease in recurrence with 5 y of tamoxifen vs. placebo
B-24, 1999 (116)DCIS43% decrease in IBC, 32% decrease in NIBC with tamoxifen vs. placebo
BCPT, 1998 (5)Healthy, moderate-risk women49% decrease in IBC, 40% decrease in NIBC with tamoxifen vs. placebo

Abbreviations: BCPT, Breast Cancer Prevention Trial; DES, diethylstilbestrol; DCIS, ductal carcinoma in situ; EBCTCG, Early Breast Cancer Trialists' Collaborative Group; IBC, invasive breast cancer; NIBC, noninvasive breast cancer.

aHormone receptor status was not measured prior to enrollment on trial.